Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
25 November 2011
(56.75 Kb 16 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 24 November 2011